Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have announced the launch of a joint initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals. This collaborative effort provides a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies.
Studies submitted for generic drug applications must demonstrate scientifically that a generic drug is "bioequivalent." These studies help demonstrate that the generic drug performs in the same manner as the brand name drug. The FDA and the regulatory authorities in the European Union (EU) inspect facilities that conduct these studies to ensure data submitted to the agencies are reliable.
Taking part in this initiative are the EMA and the EU member states France, Germany, Italy, the Netherlands and the United Kingdom.
"Our continued collaboration with the EMA and the EU enhances our ability to leverage inspection resources and helps us meet the challenges of increased globalization in drug development," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "By streamlining the inspection process for generic drug applications, we will help consumers gain access to safe and effective generic drugs."
Key objectives of the initiative are to:
This initiative will be implemented using the confidentiality arrangements established among the European Commission, the EMA, interested EU member states and the FDA.
This agreement includes an 18-month pilot phase and follows on the successful 2009 EMA-FDA Good Clinical Practices (GCP) Initiative, designed by the agencies to ensure that clinical trials data submitted in new drug applications in the United States and Europe are conducted ethically and are reliable.
For more information:
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Regulatory Affairs / Drug Approvals category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
FDA. "FDA and European Medicines Agency launch generic drug application inspections initiative." Medical News Today. MediLexicon, Intl., 20 Dec. 2013. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/270466>
FDA. (2013, December 20). "FDA and European Medicines Agency launch generic drug application inspections initiative." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270466.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.